UC San Diego researcher Ludmil Alexandrov and a cross-institution team have landed Curebound’s $1 million Cure Prize to build an artificial-intelligence system aimed at catching pancreatic cancer earlier, when doctors still have a real shot at curing it. Over several years, the group plans to pull together multiple streams of data so tumors can be flagged at stages where curative treatment is far more likely.
How the award was announced
The project surfaced in a Curebound news release naming Alexandrov alongside Moores Cancer Center surgeon Diane Simeone, UC Berkeley computer scientist Adam Yala and UC San Diego Health’s Karandeep Singh as co-investigators on a “multi-modal artificial intelligence framework” for early pancreatic-cancer detection. The Cure Prize is the single largest award in Curebound’s latest funding round, which totals $8.5 million spread across 23 cancer-research projects. The organization framed the prize as a push for translational work with a clear line of sight to the clinic, according to BusinessWire.
What the team will build
The group’s proposal centers on a multi-modal framework that blends imaging, clinical records and genomic signals into a single predictive system rather than leaning on any one test alone. Those slide-level and multimodal AI strategies build on techniques Alexandrov’s lab has already developed for reading routine biopsy material and turning it into information doctors can actually use in real time, as described by UC San Diego Today.
Why early detection matters
Speaking to the San Diego Business Journal, Alexandrov laid out the brutal math behind pancreatic cancer: stage-one cases can see survival rates around 80 to 85 percent, while stage-three and stage-four disease typically comes in under 5 percent. That crash in survival odds is the core reason the team argues that reliable early detection could dramatically change patient outcomes.
Alexandrov's track record
Alexandrov is a computational biologist whose group has published AI protocols that spot clinically relevant genomic markers from pathology slides, and he has previously received Curebound support for related precision-oncology research. A local industry profile notes that some of the lab’s ideas are already moving toward commercialization through a San Diego spin-out focused on delivering slide-based AI diagnostics directly to clinicians, underscoring a pipeline that runs from research bench to real-world product. Biocom details that work.
What Curebound says
Curebound leaders describe the Cure Prize as tailor-made for collaborative, translational projects with the potential to shift medical practice in short order. “Curebound identified these recipients based on their scientific strengths and ability to translate research breakthroughs into life-saving treatments quickly,” Chief Science Advisor Dr. Ezra Cohen said in the organization’s announcement, according to BusinessWire.
What’s next
The next phase takes the project from proposal to hands-on model-building and validation with clinical partners at UC San Diego and collaborators at Berkeley. The team has set milestones to test individual components first, then evaluate the full combined system across clinical datasets over time. Curebound notes that its grants are structured around translational milestones and cross-institutional collaboration, with an eye toward shrinking the distance from algorithm to trial to standard patient care, according to Curebound.
